The Danish Medicines Agency has announced plans to establish a first-of-its-kind data analysis center within its premises by the end of this year with the ability to analyze raw data in the pre-market phase and to scrutinize a variety of real-world data sources in the post-marketing stage, covering both drugs and medical devices.
When the center achieves full functionality, the Danish agency says it will become the first EU national competent authority to be able to analyze raw clinical data generated by companies....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?